Evidence map›Paper›PMID 42146060›Full record

ArticleFrontiers in microbiology2026

Mucinase from

Jun Liu, Lingpeng Zhan, Chengjing Xu, Runling Wei, Chengyu Bai, Miao Guan, Zhenglong Sun

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jun LiuInterdisciplinary Research Group on Microscopic Imaging and Drug Development, Shenzhen Bay Laboratory, Shenzhen, China.
Lingpeng Zhan *Institute of Chemical Biology, Shenzhen Bay Laboratory, Shenzhen, China.
Chengjing Xu *Interdisciplinary Research Group on Microscopic Imaging and Drug Development, Shenzhen Bay Laboratory, Shenzhen, China.
Runling Wei *Interdisciplinary Research Group on Microscopic Imaging and Drug Development, Shenzhen Bay Laboratory, Shenzhen, China.
Chengyu Bai *Interdisciplinary Research Group on Microscopic Imaging and Drug Development, Shenzhen Bay Laboratory, Shenzhen, China.
Miao Guan *Interdisciplinary Research Group on Microscopic Imaging and Drug Development, Shenzhen Bay Laboratory, Shenzhen, China.
Zhenglong SunInterdisciplinary Research Group on Microscopic Imaging and Drug Development, Shenzhen Bay Laboratory, Shenzhen, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mucinous cancers are characterized by tumor gland cells secreting copious amounts of mucus that forms gel-like structures. Pseudomyxoma peritonei (PMP), a rare yet prototypical mucinous malignancy, exemplifies this pathology. Biologically inert mucus coats tumor cells, promoting colonization, immune evasion, and chemoresistance. Pathological mucus accumulation leads to intra-abdominal hypertension, refractory abdominal pain, abdominal adhesions, and intestinal obstruction because of the lack of rapid, efficient, and safe clinical strategies for mucin clearance. Current management relies on extensive cytoreductive surgery to excise tumor masses and adherent mucus. Here, we present an integrated workflow spanning intestinal probiotic protease discovery for the development of mucolytic therapy. By cultivating

Indexed as

Bacteroides thetaiotaomicronM60 metalloproteinasemucinasesmucinous carcinomamucolytic therapypseudomyxoma peritonei

Identifiers

PMID42146060
PMCPMC13176161

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.